Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca appoints head of oncology

Dr Jamie Freedman joins from AZ subsidiary MedImmune

AZ Dr Jamie FreedmanAstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi.

Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca's biologics portfolio.

Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.

He also brings experience from biotech Locus Pharmaceuticals, where he was president, chief executive officer and chief medical officer, and Merck & Co, where he held several leadership roles in clinical pharmacology, oncology and experimental medicines.

12th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics